Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CASH FLOWS

v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Cash flows from operating activities:    
Net loss $ (3,314) $ (3,928)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock compensation expense 352 695
Fair value adjustment of common stock warrants (10) (9)
Depreciation 34 16
Reclassified loss of foreign exchange translation 142 0
Loss on disposal of property and equipment 0 17
Amortization of intangible assets 209 160
Accrued interest on convertible note receivable (33) (33)
Deferred tax liability (81) (83)
Accrued interest promissory note payable 5 4
Changes in operating assets and liabilities:    
Accounts receivable 102 (250)
Prepaid expenses (13) (40)
Other current assets (33) (81)
Deferred financing costs (162) 0
Accounts payable, accrued expenses and other liabilities 101 (483)
Deferred revenue 108 0
Current assets and liabilities from discontinued operations, net 0 177
Net cash used in operating activities (2,593) (3,838)
Cash flows from investing activities:    
Acquisition of property and equipment (22) (119)
Cash received from acquisition 0 476
Issuance of note receivable 0 (300)
Net cash provided by investing activities (22) 57
Cash flows from financing activities:    
Proceeds from at-the-market facility 6 0
Net cash provided by financing activities 6 0
Net decrease in cash and cash equivalents (2,609) (3,781)
Cash and cash equivalents as of beginning of year 4,039 7,820
Cash and cash equivalents as of end of year 1,430 4,039
Supplemental disclosure of non-cash activities:    
Warrants received in exchange for services 0 75
Shares issued in CollabRx acquisition 0 932
Note Receivable used as consideration for CollabRx acquisition 0 300
Promissory Note issued in CollabRx acquisition 0 500
Fair value of assets acquired in CollabRx acquisition 0 2,253
Liabilities assumed in CollabRx acquisition 0 997
Amount receivable from stock option exercise $ 35 $ 0